MyOme Launches First Integrated Polygenic Risk Score for Prostate Cancer to Advance Early Detection and Personalized Prevention
New whole-genome test uncovers hidden genetic risk beyond traditional screening, empowering earlier and more precise care for millions of men. MyOme, a leading clinical whole-genome testing and polygenic risk modeling (PRS) company, today announced the launch of its Prostate Cancer Integrated Polygenic Risk Score™ (iPRS) test – a groundbreaking test designed to identify men at […]